Distinct Phosphorylation Clusters Determine the Signaling Outcome of Free Fatty Acid Receptor 4/G Protein–Coupled Receptor 120

It is established that long-chain free fatty acids including ω-3 fatty acids mediate an array of biologic responses through members of the free fatty acid (FFA) receptor family, which includes FFA4. However, the signaling mechanisms and modes of regulation of this receptor class remain unclear. Here, we employed mass spectrometry to determine that phosphorylation of mouse (m)FFAR4 occurs at five serine and threonine residues clustered in two separable regions of the C-terminal tail, designated cluster 1 (Thr347, Thr349, and Ser350) and cluster 2 (Ser357 and Ser361). Mutation of these phosphoacceptor sites to alanine completely prevented phosphorylation of mFFA4 but did not limit receptor coupling to extracellular signal regulated protein kinase 1 and 2 (ERK1/2) activation. Rather, an inhibitor of Gq/11 proteins completely prevented receptor signaling to ERK1/2. By contrast, the recruitment of arrestin 3, receptor internalization, and activation of Akt were regulated by mFFA4 phosphorylation. The analysis of mFFA4 phosphorylation-dependent signaling was extended further by selective mutations of the phosphoacceptor sites. Mutations within cluster 2 did not affect agonist activation of Akt but instead significantly compromised receptor internalization and arrestin 3 recruitment. Distinctly, mutation of the phosphoacceptor sites within cluster 1 had no effect on receptor internalization and had a less extensive effect on arrestin 3 recruitment but significantly uncoupled the receptor from Akt activation. These unique observations define differential effects on signaling mediated by phosphorylation at distinct locations. This hallmark feature supports the possibility that the signaling outcome of mFFA4 activation can be determined by the pattern of phosphorylation (phosphorylation barcode) at the C terminus of the receptor.

[1]  D. Im Functions of omega-3 fatty acids and FFA4 (GPR120) in macrophages. , 2016, European journal of pharmacology.

[2]  Wen-bo Wang,et al.  FFA4 receptor (GPR120): A hot target for the development of anti-diabetic therapies. , 2015, European journal of pharmacology.

[3]  Stuart Maudsley,et al.  MINIREVIEW—EXPLORING THE BIOLOGY OF GPCRS: FROM IN VITRO TO IN VIVO Fulfilling the Promise of "Biased" G Protein–Coupled Receptor Agonism , 2015 .

[4]  B. Hudson,et al.  Characterizing pharmacological ligands to study the long‐chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4 , 2015, British journal of pharmacology.

[5]  A. Mancini,et al.  GPR40 agonists for the treatment of type 2 diabetes: life after ‘TAKing’ a hit , 2015, Diabetes, obesity & metabolism.

[6]  A. Ichimura,et al.  A novel antidiabetic therapy: free fatty acid receptors as potential drug target. , 2015, Current diabetes reviews.

[7]  S. Hadjadj,et al.  Contribution of the low-frequency, loss-of-function p.R270H mutation in FFAR4 (GPR120) to increased fasting plasma glucose levels , 2015, Journal of Medical Genetics.

[8]  K. Kaku,et al.  Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial , 2015, Diabetes, obesity & metabolism.

[9]  A. Hirasawa,et al.  Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion. , 2015, Endocrinology.

[10]  D. Poole,et al.  Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity , 2014, Front. Pharmacol..

[11]  A. Ichimura,et al.  Free fatty acid receptors as therapeutic targets for the treatment of diabetes , 2014, Front. Pharmacol..

[12]  Takafumi Hara,et al.  Role of free fatty acid receptors in the regulation of energy metabolism. , 2014, Biochimica et biophysica acta.

[13]  L. Luttrell,et al.  Arrestin-dependent Angiotensin AT1 Receptor Signaling Regulates Akt and mTor-mediated Protein Synthesis* , 2014, The Journal of Biological Chemistry.

[14]  B. Hudson,et al.  Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists , 2014, Front. Endocrinol..

[15]  J. Collins,et al.  Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). , 2014, Bioorganic & medicinal chemistry letters.

[16]  J. Violin,et al.  Biased ligands at G-protein-coupled receptors: promise and progress. , 2014, Trends in pharmacological sciences.

[17]  R. Evans,et al.  A Gpr120 Selective Agonist Improves Insulin Resistance and Chronic Inflammation , 2014, Nature Medicine.

[18]  Y. Zhuo,et al.  Identification of Receptor Binding-induced Conformational Changes in Non-visual Arrestins* , 2014, The Journal of Biological Chemistry.

[19]  B. Hudson,et al.  The Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4 (FFA4/GPR120)* , 2014, The Journal of Biological Chemistry.

[20]  B. Hudson,et al.  Concomitant Action of Structural Elements and Receptor Phosphorylation Determines Arrestin-3 Interaction with the Free Fatty Acid Receptor FFA4* , 2014, The Journal of Biological Chemistry.

[21]  D. Polidori,et al.  Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice , 2014, The Journal of Biological Chemistry.

[22]  N. Morgan,et al.  GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans , 2014, Diabetologia.

[23]  S. Offermanns Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. , 2014, Annual review of pharmacology and toxicology.

[24]  B. Hudson,et al.  The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35 , 2014, Molecular Pharmacology.

[25]  T. Schwartz,et al.  Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. , 2013, Molecular metabolism.

[26]  B. Hudson,et al.  Drugs or diet? – Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs , 2013, British journal of pharmacology.

[27]  A. Mancini,et al.  The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? , 2013, Trends in endocrinology and metabolism.

[28]  A. Kruse,et al.  Structure of active β-arrestin1 bound to a G protein-coupled receptor phosphopeptide , 2013, Nature.

[29]  B. Hudson,et al.  Discovery of a potent and selective GPR120 agonist. , 2012, Journal of medicinal chemistry.

[30]  P. Elliott,et al.  Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human , 2012, Nature.

[31]  R. Lefkowitz,et al.  β-Arrestin-mediated receptor trafficking and signal transduction. , 2011, Trends in pharmacological sciences.

[32]  Ryan T. Strachan,et al.  Distinct Phosphorylation Sites on the β2-Adrenergic Receptor Establish a Barcode That Encodes Differential Functions of β-Arrestin , 2011, Science Signaling.

[33]  A. Tobin,et al.  Differential G-protein-coupled Receptor Phosphorylation Provides Evidence for a Signaling Bar Code* , 2010, The Journal of Biological Chemistry.

[34]  B. Hudson,et al.  Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of β-arrestin-2 and activate Gα13. , 2010, The Biochemical journal.

[35]  J. Wess,et al.  M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1 , 2010, Proceedings of the National Academy of Sciences.

[36]  S. Watkins,et al.  GPR120 Is an Omega-3 Fatty Acid Receptor Mediating Potent Anti-inflammatory and Insulin-Sensitizing Effects , 2010, Cell.

[37]  F. Spinella,et al.  β-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinaseThis article is one of a selection of papers published in the two-part special issue entitled 20 Years of Endothelin Research. , 2010 .

[38]  T. Hakoshima,et al.  Structural basis for the specific inhibition of heterotrimeric Gq protein by a small molecule , 2010, Proceedings of the National Academy of Sciences.

[39]  L. Luttrell,et al.  Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling , 2010, Pharmacological Reviews.

[40]  F. Spinella,et al.  Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. , 2010, Canadian journal of physiology and pharmacology.

[41]  A. M. Habib,et al.  Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells , 2009, Diabetologia.

[42]  A. Tobin,et al.  Location, location, location…site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling , 2008, Trends in pharmacological sciences.

[43]  A. Tobin G‐protein‐coupled receptor phosphorylation: where, when and by whom , 2008, British journal of pharmacology.

[44]  A. Marchese,et al.  G protein-coupled receptor sorting to endosomes and lysosomes. , 2008, Annual review of pharmacology and toxicology.

[45]  G. Milligan,et al.  Up-regulation of the Angiotensin II Type 1 Receptor by the MAS Proto-oncogene Is Due to Constitutive Activation of Gq/G11 by MAS* , 2006, Journal of Biological Chemistry.

[46]  Eric Reiter,et al.  GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.

[47]  Eric Reiter,et al.  GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. , 2006, Trends in endocrinology and metabolism: TEM.

[48]  G. Tsujimoto,et al.  Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 , 2005, Nature Medicine.

[49]  M. Taniguchi,et al.  A Novel Gαq/11-selective Inhibitor* , 2004, Journal of Biological Chemistry.

[50]  M. Taniguchi,et al.  A novel Galphaq/11-selective inhibitor. , 2004, The Journal of biological chemistry.

[51]  K. Palczewski,et al.  Sequential phosphorylation of rhodopsin at multiple sites. , 1993, Biochemistry.